SI-BONE, Inc. reports developments for a medical device business focused on procedural solutions for compromised bone and sacropelvic disorders. The company develops technologies centered on spinopelvic anatomy, including applications in minimally invasive SI joint fusion, adult spinal deformity, spinopelvic and sacropelvic fixation, and pelvic trauma.
Recurring updates include quarterly and annual financial results, revenue guidance, cash flow and adjusted EBITDA commentary, physician adoption metrics, reimbursement developments, and healthcare conference presentations. Product references include the iFuse Implant System, iFuse Bedrock Granite, iFuse TORQ, iFuse TORQ TNT, iFuse 3D, and related surgical implant technologies.
SI-BONE, Inc. expands its product line with the launch of the Granite 9.5 implant, designed for sacroiliac fusion and spinopelvic fixation. The smaller diameter implant received FDA clearance in January 2024. Surgeons praise the implant for its ease of use and potential for improved patient outcomes. The company aims to target a large market with the new offering.
SI-BONE, Inc. reported financial results for the first quarter of 2024, showing worldwide revenue of $37.9 million, a 16% growth from the prior year. The company's U.S. revenue also increased by 16%, with a gross margin of 79%. SI-BONE is optimistic about revenue growth acceleration, driven by new product launches and market expansion. The company updated its 2024 revenue guidance to $164 million - $166 million, indicating a growth of 18% - 20%.
SI-BONE, a medical device company dedicated to musculoskeletal disorders, will be presenting at the 2024 BofA Securities Healthcare Conference. Investors can join the fireside chat on May 14, 2024, at 2:20 p.m. Eastern Time. The webcast will be accessible for replay for 90 days.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.